5alpha-二氢炔诺酮 | 52-79-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 5alpha-二氢炔诺酮
• 英文名称: [3H]-5alpha-Dihydrorethindrone
• 英文别名: 5alpha-Dihydrorethindrone；17β-Hydroxy-19-nor-5α,17α-pregn-20-yn-3-one；17α-ethinyl-17β-hydroxy-5α-estran-3-one；5α-dihydronorethisterone；17-hydroxy-19-nor-5α,17βH-pregn-20-yn-3-one；17-Hydroxy-19-nor-5α,17βH-pregn-20-in-3-on；(5S,8R,9R,10S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,4,5,6,7,8,9,10,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-one
• CAS: 52-79-9
• 化学式: C₂₀H₂₈O₂
• 分子量: 300.441
• InChiKey: OMGILQMNIZWNOK-XDQPPUBWSA-N

物化性质

• 熔点：
  216-218°C
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5alpha-二氢炔诺酮 在 sodium tetrahydroborate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 1.0h， 以90%的产率得到3β，5α-四氢炔诺酮
  参考文献：
  名称：

  去甲睾酮的马代谢物：一系列 19-Nor-17α-孕二醇和 19-Nor-17α-孕三醇的合成

  摘要：

  已合成了一系列 19-nor-17α-孕二醇和 19-nor-17α-孕三醇，并用于确认合成代谢类固醇去甲睾酮的主要马尿代谢物的结构 (1)。19-Nor-5α,17α-pregnane-3α,17β-二醇 (2), 19-nor-5α,17α-pregnane-3β,17β-二醇 (4), 19-nor-5β,17α-pregnane-3α, 17β-二醇 (6) 和 19-nor-5β,17α-pregnane-3β,17β-二醇 (7) 通过立体选择性还原炔诺酮的 3-ene-4-one 制备。19-nor-5α,17α-pregnane-3β,16α,17β-triol (8) 和 19-nor-5α,17α-pregnane-3β,16β,17β-triol (9) 从 19-nortestosterone (11 ) 通过多步过程，其中关键步骤涉及格氏加成到 16-acetoxy-17-ones。三醇

  DOI：

  10.1071/ch03018
• 作为产物：
  描述：

  炔诺酮 在 氨 、 lithium 作用下， 以 1,4-二氧六环 为溶剂， 以63%的产率得到5alpha-二氢炔诺酮
  参考文献：
  名称：

  去甲睾酮的马代谢物：一系列 19-Nor-17α-孕二醇和 19-Nor-17α-孕三醇的合成

  摘要：

  已合成了一系列 19-nor-17α-孕二醇和 19-nor-17α-孕三醇，并用于确认合成代谢类固醇去甲睾酮的主要马尿代谢物的结构 (1)。19-Nor-5α,17α-pregnane-3α,17β-二醇 (2), 19-nor-5α,17α-pregnane-3β,17β-二醇 (4), 19-nor-5β,17α-pregnane-3α, 17β-二醇 (6) 和 19-nor-5β,17α-pregnane-3β,17β-二醇 (7) 通过立体选择性还原炔诺酮的 3-ene-4-one 制备。19-nor-5α,17α-pregnane-3β,16α,17β-triol (8) 和 19-nor-5α,17α-pregnane-3β,16β,17β-triol (9) 从 19-nortestosterone (11 ) 通过多步过程，其中关键步骤涉及格氏加成到 16-acetoxy-17-ones。三醇

  DOI：

  10.1071/ch03018

文献信息

• Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
  申请人：Wang Changjin

  公开号：US20100087402A1

  公开（公告）日：2010-04-08

  The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.

  本发明涉及治疗依赖雌激素的子宫过度增生性疾病，包括子宫内膜异位症、子宫肌瘤、子宫内膜增生、子宫癌及其相关症状，通过阴道给药至少两种活性药物，所选药物包括芳香化酶抑制剂、抗炎药和子宫选择性雌激素受体拮抗剂。这种联合疗法降低了局部雌激素产生，阻断了局部雌激素作用，并在局部抑制了炎症，导致对依赖雌激素的疾病组织的饥饿，缓解相关症状，延缓疾病进展。阴道给药最大限度地抑制了局部雌激素产生，而不显著影响全身循环雌激素水平。这导致增强的临床疗效和减少的副作用。
• composition and uses for influencing hair growth
  申请人：Schmidt Alfred

  公开号：US20110117218A1

  公开（公告）日：2011-05-19

  The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5α reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described.

  该发明描述了一种组合物，该组合物包括至少一种从化学合成芳香化酶抑制剂和大豆和油菜籽提取物中选择的芳香化酶抑制剂和至少一种植物提取物，该植物提取物含有从植物中提取的一个或多个活性成分，所述活性成分从5α还原酶I型和/或II型抑制剂和雄激素受体阻断剂中选择，该组合物例如包含在一种组合物中，并具有影响头发生长的特殊性质。还描述了该组合物的用途。
• COMPOSITION CONTAINING 5$g(a)-DIHYDRO-19-NORETHYSTERONE AND ITS DERIVATIVES CAPABLE OF INHIBITING AROMATASE IN VIVO
  申请人：MEDICAL FOUNDATION OF BUFFALO, INC.

  公开号：EP0417281A1

  公开（公告）日：1991-03-20

  A composition used for inhibiting aromatase in vivo in mammals and containing 5α-dihydro-19-norethysterone (5α-DHNET or its acyl derivative is disclosed. This composition comprises a compound represented by general formula (I) (wherein R, represents hydrogen or C₁₋₂₀ acyl) and a medicinally acceptable carrier or diluent. This composition can be effectively utilized for treatment or prophylaxis ofendocrine dependence of mammals such as mammary cancer, uterine cancer, etc.

  本发明公开了一种用于抑制哺乳动物体内芳香化酶的组合物，其中含有 5α-dihydro-19-norethysterone (5α-DHNET) 或其酰基衍生物。这种组合物由通式 (I) 所代表的化合物（其中 R, 代表氢或 C₁₋₂₀酰基）和医学上可接受的载体或稀释剂组成。该组合物可有效用于治疗或预防哺乳动物的内分泌依赖性疾病，如乳腺癌、子宫癌等。
• Composition and uses for influencing hair growth
  申请人：S.W. Patentverwertungs Limited

  公开号：US11052059B2

  公开（公告）日：2021-07-06

  The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5α reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described.

  本发明描述了至少一种芳香化酶抑制剂（分别选自化学合成芳香化酶抑制剂和具有芳香化酶抑制作用的大豆和油菜籽萃取物）与至少一种植物萃取物的组合，该植物萃取物含有一种或多种从植物中提取的活性成分物质，这些活性成分物质选自 5α 还原酶 I 型和/或 II 型抑制剂以及雄激素受体阻断剂。此外，还介绍了这种组合物的用途。
• Aromatase marking
  申请人：——

  公开号：US20040241087A1

  公开（公告）日：2004-12-02

  Compounds are described which exhibit an inhibitory action towards the enzyme aromatase and which comprise at least one detectable group. Such compounds are excellently suitable for medical diagnosis and/or for therapy, particularly for tumor diseases and above all for breast cancer.

  所述化合物对芳香化酶具有抑制作用，并包含至少一个可检测基团。这些化合物非常适合医学诊断和/或治疗，特别是肿瘤疾病，尤其是乳腺癌。